Is neoadjuvant chemotherapy the optimal treatment for primary resectable pancreatic cancer?

被引：0
|
作者：
Wang, Yu-song [1 ]
机构：
[1] Second Mil Med Univ, Sch Basic Med Sci, Shanghai 200438, Peoples R China
来源：
HPB | 2020年 / 22卷 / 05期
关键词：
D O I：
10.1016/j.hpb.2020.02.012
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：790 / 790
页数：1
相关论文
共 50 条
  • [41] Neoadjuvant chemoradiotherapy for resectable pancreatic cancer
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (05): : 392 - 392
  • [42] Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy
    Javed, Ammar A.
    Wright, Michael J.
    Siddique, Ayat
    Blair, Alex B.
    Ding, Ding
    Burkhart, Richard A.
    Makary, Martin
    Cameron, John L.
    Narang, Amol
    Herman, Joseph
    Zheng, Lei
    Laheru, Daniel
    Weiss, Matthew J.
    Wolfgang, Christopher
    He, Jin
    JOURNAL OF GASTROINTESTINAL SURGERY, 2019, 23 (01) : 112 - 121
  • [43] OUTCOME OF PATIENTS WITH BORDERLINE RESECTABLE PANCREATIC CANCER IN THE CONTEMPORARY ERA OF NEOADJUVANT CHEMOTHERAPY
    Javed, Ammar A.
    Siddique, Ayat
    Blair, Alex
    Parish, Lindsay
    Burkhart, Richard
    Weiss, Matthew J.
    Cameron, John
    Narang, Amol
    Zheng, Lei
    Laheru, Daniel
    Wolfgang, Christopher L.
    He, Jin
    GASTROENTEROLOGY, 2018, 154 (06) : S1265 - S1265
  • [44] Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy
    Ammar A. Javed
    Michael J. Wright
    Ayat Siddique
    Alex B. Blair
    Ding Ding
    Richard A. Burkhart
    Martin Makary
    John L. Cameron
    Amol Narang
    Joseph Herman
    Lei Zheng
    Daniel Laheru
    Matthew J. Weiss
    Christopher Wolfgang
    Jin He
    Journal of Gastrointestinal Surgery, 2019, 23 : 112 - 121
  • [45] Efficacy of Neoadjuvant Chemotherapy Using Gemcitabine and S-1 for Resectable and Borderline Resectable Pancreatic Cancer
    Aoki, T.
    Mori, S.
    Sakuraoka, Y.
    Suzuki, T.
    Nishi, Y.
    Arakawa, T.
    Shimizu, T.
    Tago, K.
    Park, K. H.
    Harada, N.
    Shiraki, T.
    Iso, Y.
    Kubota, K.
    PANCREAS, 2019, 48 (10) : 1404 - 1404
  • [46] A Qualitative Review of Neoadjuvant Chemotherapy in Resectable Pancreatic Adenocarcinoma
    Blair, Alex B.
    Sorber, Rebecca
    Rozich, Noah S.
    Burkhart, Richard A.
    PANCREAS, 2019, 48 (08) : 973 - 984
  • [47] Neoadjuvant chemotherapy improves outcomes in resectable pancreatic adenocarcinoma
    Christopher, Wade
    Nassoiy, Sean
    Marcus, Rebecca
    Keller, Jennifer
    Chang, Shu-Ching
    Fischer, Trevan
    Bilchik, Anton
    Goldfarb, Melanie
    SURGERY IN PRACTICE AND SCIENCE, 2022, 11
  • [48] The Fate of Resectable Pancreatic Adenocarcinoma After Neoadjuvant Chemotherapy
    Irfan, Ahmer
    Rose, J. Bart
    Wang, Thomas N.
    Vickers, Selwyn M.
    Dudeja, Vikas
    Gbolahan, Olumide
    Reddy, Sushanth
    PANCREAS, 2022, 51 (01) : 100 - 105
  • [49] Neoadjuvant treatment for resectable pancreatic cancer: Time for phase III testing?
    Reni, Michele
    WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (39) : 4883 - 4887
  • [50] Neoadjuvant Treatment in Resectable Pancreatic Cancer: A Double-edged Sword?
    Solomon, D.
    Leigh, N. L.
    Feingold, D.
    Liu, P. H.
    Bolton, N.
    Kim, J. J.
    Magge, D. R.
    Golas, B. J.
    Sarpel, U.
    Labow, D. M.
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : S133 - S133
12345